Replies to post #1602 on Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Wow. The P2 Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) started recruiting patients as of March 17th. A month ago they estimated study start date as April. So that was pretty quick. They're not kidding this time. We really could see results this year.

PS Just realized the study started on St. Patty's Day. Maybe it will have the luck of the Irish to move it along :)

[antihama]

Significant change to the EGFR Exon 20 Mutation trial. They doubled the trial size to 60. An additional cohort of 30 patients will be treated for HER2 exon 20 mutant NSCLC. A quick search gives a little more color

Targeting HER2 in NSCLC Remains Work in Progress
Jason M. Broderick @jasoncology
Published Online: Sunday, Aug 02, 2015

Although targeting HER2 mutations is primarily associated with breast cancer, there may be therapeutic potential with anti-HER2 agents in non–small cell lung cancer (NSCLC). At the 2015 International Lung Cancer Congress, Corey Langer, MD, discussed the potential for afatinib and neratinib—dual inhibitors of EGFR and HER2—in NSCLC and the need for additional research to truly understand HER2 targeted therapy in this setting.

HER2 mutations occur in about 2% to 4% of patients with NSCLC and for the most part, they are mutually exclusive with other molecular drivers (eg, EGFR, KRAS), according to Langer, director of Thoracic Oncology at the Abramson Cancer Center of the University of Pennsylvania. “Similar to EGFR and ALK, the HER2 mutations are more common in women, never-smokers, and adenocarcinoma histology,” Langer added...

http://www.onclive.com/web-exclusives/targeting-her2-in-nsclc-remains-a-work-in-progress